Medscape InDiscussion: MASLD

Medscape
  • 0.0（0）
  • 医学

Listen to Medscape InDiscussion: MASLD, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

エピソード

  1. 7月23日

    Incidental Fatty Liver on Imaging: What Should You Do Next?

    When fatty liver appears incidentally on imaging, "just lose weight" isn't enough. Dr Brandman explains how to use FIB-4, FibroScan, and ELF to triage who needs referral and who doesn't. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep3-2026a1000aav. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview MetALD: Clinical Aspects, Pathophysiology and Treatment https://pubmed.ncbi.nlm.nih.gov/39897615/ Cirrhosis https://emedicine.medscape.com/article/185856-overview The Role of FibroScan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/ Magnetic Resonance Elastography of the Liver: Everything You Need to Know to Get Started https://pmc.ncbi.nlm.nih.gov/articles/PMC9538666/ A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/39131248/ Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis https://pmc.ncbi.nlm.nih.gov/articles/PMC11240480/ Viral Hepatitis https://emedicine.medscape.com/article/775507-overview Autoimmune Hepatitis (AIH) https://emedicine.medscape.com/article/172356-overview FibroSURE as a Noninvasive Marker of Liver Fibrosis and Inflammation in Chronic Hepatitis B https://pubmed.ncbi.nlm.nih.gov/24990385/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  2. 6月25日

    Is Alcohol the Missing Piece in Your MASLD Workup?

    Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep2-2026a1000aau. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review https://pubmed.ncbi.nlm.nih.gov/28100008/ Practical Guide, Challenges, and Pitfalls in Liver Fibrosis Staging https://pubmed.ncbi.nlm.nih.gov/37536882/ Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/29378307/ A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature https://pubmed.ncbi.nlm.nih.gov/37363821/ Phosphatidylethanol in Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/40759197/ Phosphatidylethanol and Self-Reported Alcohol Intake to Subclassify Individuals at Risk of Steatotic Liver Disease: An Analysis of Data From a Prospective Cohort Study https://pubmed.ncbi.nlm.nih.gov/40945520/ The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test https://pubmed.ncbi.nlm.nih.gov/9738608/ Elevated ALT/AST Ratio as a Marker for NAFLD Risk and Severity: Insights From a Cross-Sectional Analysis in the United States https://pubmed.ncbi.nlm.nih.gov/39253584/ Alcohol Use Disorder: A Comparison Between DSM–IV and DSM–5 https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-use-disorder-comparison-between-dsm Wilson Disease https://emedicine.medscape.com/article/183456-overview Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  3. 6月25日

    Can Primary Care Catch MASLD Before Cirrhosis?

    MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1 The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36626630/ AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/36727674/ Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41812830/ FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis Noninvasive Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease https://pubmed.ncbi.nlm.nih.gov/41640956/ NAFLD: Reporting Histologic Findings in Clinical Practice https://pubmed.ncbi.nlm.nih.gov/33111374/ Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study https://pubmed.ncbi.nlm.nih.gov/37127100/ Cause-Specific Mortality in 13,099 Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease in Sweden https://pubmed.ncbi.nlm.nih.gov/40139508/ Liver Function Tests https://www.ncbi.nlm.nih.gov/books/NBK482489/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  • 3話のエピソード

番組について

Listen to Medscape InDiscussion: MASLD, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep1-2026a1000aat. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

情報

  • クリエイター
    Medscape
  • 配信期間
    26年
  • エピソード
    3
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © Copyright 2026, Medscape
  • 番組のWebサイト
    Medscape InDiscussion: MASLD